Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer.
about
Targeted drugs in small-cell lung cancerTreatment for small cell lung cancer, where are we now?-a reviewTargeting angiogenesis in small cell lung cancerNew and emerging developments in extensive-stage small cell lung cancer therapeuticsCheckpoint inhibitors in lung cancer: latest developments and clinical potentialImmune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel?VAC chemotherapy with valproic acid for refractory/relapsing small cell lung cancer: a phase II studyTwenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing resultsPhase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer.A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.Phase II study of sequential topotecan and etoposide in patients with intermediate grade non-Hodgkin's lymphoma: a National Cancer Institute of Canada Clinical Trials Group study.Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancerPhase I trial of weekly topotecan and gemcitabine in patients with solid tumors.Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancerSystematic Review of topotecan (Hycamtin) in relapsed small cell lung cancer.Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304).Efficacy and safety of amrubicin hydrochloride for treatment of relapsed small cell lung cancer.Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study.A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancerPhase-II trial of rebeccamycin analog, a dual topoisomerase-I and -II inhibitor, in relapsed "sensitive" small cell lung cancerPhase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer.Retrospective analysis of Japanese patients with relapse or refractory small-cell lung cancer treated with amrubicin hydrochlorideA phase I clinical trial of weekly oral topotecan for relapsed small cell lung cancer.Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase.Lesser Toxicities of Belotecan in Patients with Small Cell Lung Cancer: A Retrospective Single-Center Study of Camptothecin Analogs.Meta-analysis of the role of bevacizumab in extensive stage small cell lung cancer.Lung cancer: current diagnosis and treatmentPatient-reported outcomes are changing the landscape in oncology care: challenges and opportunities for payers.Treatment options for small cell lung cancer - do we have more choice?A prospective pilot study of genome-wide exome and transcriptome profiling in patients with small cell lung cancer progressing after first-line therapyA phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602).Novel systemic therapies for small cell lung cancerSouthwest Oncology Group S0802: a randomized, phase II trial of weekly topotecan with and without ziv-aflibercept in patients with platinum-treated small-cell lung cancer.Management of small-cell lung cancer: incremental changes but hope for the futureFast, hungry and unstable: finding the Achilles' heel of small-cell lung cancer.Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097).Topoisomerase I inhibition with topotecan: pharmacologic and clinical issues.Small cell lung cancer: therapies and targetsA systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory small-cell lung cancerThe role of anthracyclines in small cell lung cancer.
P2860
Q26767017-B111DF35-C78F-4AC5-8332-CD73631A0B10Q26767023-1766869C-738E-4B67-9A75-B2F5BCE8E4E3Q28068385-1FD78DAC-544F-4D11-8187-17406A19A887Q28076304-BBC5C748-BCED-4BF2-A188-C1F874B87C07Q28076467-DBBDF1A9-6101-4E1D-8458-D06948E625D8Q28079771-E610CF5A-422C-48A3-8A08-863808FAADD1Q28596809-9494AEA4-0F0A-44C4-8A8B-FA3BFF2DC518Q30886032-0BFFAAD1-6246-4471-83BA-3893BF3E1C1EQ33311607-4E7D8CCA-D3BC-4E85-A6A0-399A7E7EAA84Q33344326-1C4FA5CD-E11E-4838-85C9-4CF694B0922EQ33344965-492194EC-1D1F-401D-9381-96D36359DBE8Q33361868-32939CDD-A09E-4A65-9DB1-D1A60DF11C05Q33383131-CA932FD2-14F8-4AB9-8F4E-50373668455CQ33383208-BCEBD975-968E-4E3F-824E-4057AF5B4121Q33391448-AD577086-60AE-43F3-90E3-E53CAC9EC679Q33392042-3E9BC5F5-D1F2-4658-87BE-427DD4D5929CQ33393427-94B14BFB-76A6-4445-A07B-1926DABB90A2Q33395375-3EF73398-3F5B-46BD-B21C-2C68C5D4B60AQ33395544-C6C0DEFF-2555-421D-99C8-B3371E185BA5Q33400292-511C6AC1-8191-460D-8040-FAB73D48B31FQ33400716-15CC4E27-AB47-4633-9421-FFDE1F984A8EQ33403230-267C2FA4-0148-46D6-8BF3-7949EB8AF6A6Q33407183-59E4ED0D-6656-44D7-BBFD-BE8759B39E40Q33417537-4CD6F6E4-7146-4D46-BE43-403C995AFAEBQ33437893-CF88C6D4-8FDC-4073-AE41-4B0AD7E6FEC0Q33443519-668FEF4E-42F4-4524-8349-D3A113258C5BQ33554085-765E8B45-A339-43A6-8E7B-9CA882BC3849Q33652833-EF4A8CDC-BE16-484C-9228-2699669F277AQ33723735-688C6D59-E101-46A8-9E41-4B26501710D0Q33769203-D51BCFD8-8923-4162-9B78-6BC10E3892CEQ33785927-84ED78B6-9542-4EAF-80E0-A844D4CB4C45Q33862245-B90F1947-B5F1-4AF7-B20B-E36CCE854A87Q34000985-DFB7957C-EA9C-45AF-9BDD-395757346CE2Q34013813-22437583-E89E-4F49-9B56-AD4D03496F4BQ34013850-564406D8-5130-4299-849D-6F981EAA9D39Q34026037-95C72BC2-BA8E-4D0C-8F74-CB2339CCFFE6Q34240913-4A1A49ED-F436-46BE-BEB0-FCF01DB69F5FQ34250859-3E2CF2A6-674F-424E-BF8A-3BC671411B5BQ34313435-62BE1C06-B3B2-4DE2-AC38-EEAC583ED67EQ34358063-89C9D94F-75C9-498F-BD26-7149AF8DA64D
P2860
Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer.
description
1999 nî lūn-bûn
@nan
1999 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Topotecan versus cyclophospham ...... urrent small-cell lung cancer.
@ast
Topotecan versus cyclophospham ...... urrent small-cell lung cancer.
@en
Topotecan versus cyclophospham ...... urrent small-cell lung cancer.
@nl
type
label
Topotecan versus cyclophospham ...... urrent small-cell lung cancer.
@ast
Topotecan versus cyclophospham ...... urrent small-cell lung cancer.
@en
Topotecan versus cyclophospham ...... urrent small-cell lung cancer.
@nl
prefLabel
Topotecan versus cyclophospham ...... urrent small-cell lung cancer.
@ast
Topotecan versus cyclophospham ...... urrent small-cell lung cancer.
@en
Topotecan versus cyclophospham ...... urrent small-cell lung cancer.
@nl
P2093
P1476
Topotecan versus cyclophospham ...... urrent small-cell lung cancer.
@en
P2093
A Depierre
D J Stewart
F A Shepherd
J Carmichael
J H Schiller
J P Kleisbauer
J von Pawel
M C Palmer
P304
P356
10.1200/JCO.1999.17.2.658
P407
P577
1999-02-01T00:00:00Z